Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Embase; 2021.
Preprint in English | EMBASE | ID: ppcovidwho-330436

ABSTRACT

Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. We performed a head-to-head comparison of the ability of sera from individuals vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S) to recognize and neutralize SARS-CoV-2 variants of concern (VOCs;Alpha, Beta, Gamma, Delta and Omicron). Four weeks after completing the vaccination series, SARSCoV-2 wild-type neutralizing antibody titers were highest in recipients of BNT162b2 and mRNA-1273 (median titers of 1891 and 3061, respectively), and substantially lower in those vaccinated with the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S (median titers of 241 and 119, respectively). VOCs neutralization was reduced in all vaccine groups, with the largest (9 to 80-fold) reduction in neutralization being observed against the Omicron variant. Overall, the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after the second vaccination.

2.
Crit Care Med ; 49(11): 1974-1982, 2021 11 01.
Article in English | MEDLINE | ID: covidwho-1475880
3.
Nederlands Tijdschrift voor Geneeskunde ; 165(2), 2021.
Article in Dutch | EMBASE | ID: covidwho-1107025
4.
Nederlands Tijdschrift voor Geneeskunde ; 165(2), 2021.
Article in Dutch | Scopus | ID: covidwho-1080009
5.
Nederlands Tijdschrift voor Geneeskunde ; 164(16), 2020.
Article in Dutch | Scopus | ID: covidwho-826740
SELECTION OF CITATIONS
SEARCH DETAIL